Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus docetaxel as second-line treatment in advanced NSCLC
ChiCTR2500104869Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival at 6 months. Started Jun 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500104869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104869.